The Preventive and Treatment of the Neuroinflammasome in Sorokdo National Hospital

Objective: This study investigated leprosy patients with Alzheimer's disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS, Dapsone) as a neuroinflammasome competitor. Method: We searched all the Sorokdo National Hospital medical records and the National Health Insurance Service in South Korea and when the Korean government computerized the International Classification of Diseases (ICD)-9 code and Electronic Data Interchange (EDI). The Seoul study analyzed AD, and anti-AD drugs in the Sorokdo National Hospital's EDI database archived from January 2005 to June 2020 through the ICD-9 and -10 codes with National Health Insurance System. Result: The relation between DDS and AD each year was analyzed using the chi-square tests. P-values from 2007 to 2020 were significant. (P-value < 0.05) Treatment effects were proved with the T-Test Calculator. Four groups were defined: Treatment (T) 1: DDS prescription (+) AD prevalence (+), T 2: DDS (+) AD non-prevalence (-), T 3: DDS non-prescription (-) AD (+), T 4: DDS (-) AD (-). The results are all significant at p < .05. The participants with AD (T1) who took the DDS intervention (Mean (M) = 0.1766, Standard Deviation (SD) = 0.074) compared to the participants without AD (T2) who did not take the DDS in the control group (M = 0.5501, SD = 0.1421) demonstrated significantly lesser AD prevalence rates. The t-value is -8.72515 and the p-value is < .00001. The result is significant at p < 0.05. Conclusion: Our study is the first to prove dapsone as a preventive treatment for AD through observational studies for 15 years. This study demonstrated the neuroinflammasome therapy for AD.